Some non-small-cell lung cancers (NSCLC) have changes in a gene called EGFR. If your NSCLC has these mutations, your doctor likely will recommend treatment with targeted therapies that block EGFR.

Comprehensive biomarker testing can identify EGFR or other mutations in your lung cancer. Learn the benefits of testing and how it can help shape treatment.